HHS Recommends Rescheduling: Now What? | 9.14.23 | Fireside Chats with NCIA’s Government Relations Team
NCIA’s #IndustryEssentials webinar series is our premier digital educational platform featuring a variety of interactive programs allowing us to provide you timely, engaging and essential education when you need it most. The Fireside Chat series of NCIA’s #IndustryEssentials webinars are an opportunity for industry professionals to hear from our government relations team and guests about the latest developments in federal policy LIVE.
For more than fifty years, the federal government has maintained that cannabis is a Schedule I drug, meaning that it has a high potential for abuse and no accepted medical value.
That recently changed when the Department of Health and Human Services (HHS) recommended to the Drug Enforcement Administration (DEA) that cannabis be placed in Schedule III, meaning that it has moderate to low abuse potential, a currently accepted medical use, and a low potential for psychological dependence.
There’s no doubt this move was an historic one– but what does it mean? What’s next? How will it impact your business? Join NCIA’s Aaron Smith and Michelle Rutter Friberg as they unpack all these questions surrounding cannabis rescheduling impact and more!
Committee Insights | 7.26.23 | Concepts for Regulatory Consideration – Shifting the Conversation from “Cannabis vs. Hemp” to “The Cannabinoids”
NCIA’s #IndustryEssentials webinar series is our premier digital educational platform featuring a variety of interactive programs allowing us to provide you timely, engaging and essential education when you need it most.
In this edition of our NCIA Committee Insights series, originally aired on July 26, we were joined by leading cannabinoid product manufacturers and Cannabis Regulators Association (representing cannabis and hemp regulators across more than 40 states and U.S. territories) to examine different approaches to regulating consumer products containing cannabinoids across the US and discuss the potential for harmonized regulations in the future.
Regulating the cannabinoids is difficult enough, but throw in the challenges associated with cannabinoids derived from marijuana or hemp and the challenges can get even more complicated. Not to mention the debate between intoxicating and non-intoxicating cannabinoids and how to address the risks to public health and safety from these different types of cannabinoids. Then you have the proverbial “cherry on top” with how to address cannabinoids, both naturally occurring and novel, being produced by genetically modified organisms and scientists in the lab. There has got to be a logical way to solve this problem.
One potential solution is shifting the conversation away from cannabis vs. hemp and toward the constituents of concern, the cannabinoids. By regulating the cannabinoids, we can focus the debate on what matters, how to regulate cannabinoid ingredients in a way that is proportional to the level of risk to public health and safety. This ensures we have both a functional and vibrant cannabinoid products market and the means to protect consumers.
Learning Objectives:
• Learn about the similarities and differences between marijuana and hemp regulations for consumer products containing cannabinoids
• Find out what a consumer product containing cannabinoids is and how this concept can be used to promote more common sense regulations
• Listen to new perspectives on the challenges facing the cannabinoid-containing consumer products space and how to more efficiently regulate this marketplace
Curious about the complex world of cannabinoid regulation? Sit back and settle in for an insightful webinar where we delve into the challenges (and solutions!) surrounding cannabinoids derived from marijuana and hemp.
From Lab to Label: Safeguarding Consumers in the Cannabinoid Product Landscape (Part III): https://bit.ly/3Xc9Lx6
Know Your Hazards – Occupational Health and Safety Considerations in Cannabinoid Ingredient Manufacturing (Part IV): https://bit.ly/3rEUeKP
Committee Insights: Meet the Minors (Novel, Minor, Synthetic Cannabinoids – Part II)
NCIA’s #IndustryEssentials webinar series is our premier digital educational series featuring a variety of interactive programs allowing us to provide you timely, engaging and essential education when you need it most. The NCIA Committee Insights series showcases content produced in partnership with one of our 15 member-led committees.
Our multi-part series on Novel, Minor, and Synthetic Cannabinoids continues! Join members of NCIA’s Cannabis Manufacturing, Scientific Advisory and Hemp Committees for an in-depth discussion of the most talked about minor, novel, and synthetic cannabinoids.
What scientific publications exist for each compound? What do we know about each molecule’s physiological, psychoactive, and therapeutic effects?
You’ll find out LIVE from leading chemical experts, manufacturers and product development specialists as they explore these compounds from various perspectives to examine their implications for consumers, medical practitioners, patients, producers and regulators.
Learning Objectives
• Molecular Structures and Identification of novel, minor, and synthetic compounds
• Published Physiological and Psychoactive effects of these compounds
• Perceived therapeutic effects
• Opportunity to ask about other new compounds not in presentation.
Panelists
Cassin Coleman
Founder
Cassin Consulting
James Granger
Chief Political Officer
Clintel Capital Group
John Murray
President
Sustainable Innovations
Scott Seeley
Patent Attorney & Intellectual Property Lawyer
Eastgate IP
Committee Insights: NCIA Mythbusters – Is Cannabis Safer Than Alcohol?
NCIA’s #IndustryEssentials webinar series is our premier digital educational series featuring a variety of interactive programs allowing us to provide you timely, engaging and essential education when you need it most. The NCIA Committee Insights series showcases content produced in partnership with one of our 15 member-led committees.
It is estimated that more than 140,000 people die from alcohol-related causes annually, making alcohol the fourth-leading preventable cause of death in the United States. How does cannabis compare? Find out in this special edition of Mythbusters brought to you by members of NCIA’s Scientific Advisory Committee and State Regulatory Committee. As more and more states move towards adult use, business owners must learn about safe access best practices and ways to reduce harm when it comes to their consumers.
Learning Objectives
• Learn what a contraindication is
• Learn which physiological and mental health conditions should avoid THC and CBD
• Familiarize yourself with State Regulations to Avoid Harm and Increase Safe Access
• Policy Recommendations to Avoid Harm
Panelists
Paloma Lehfeldt, M.D.
Senior Director of Clinical Science and Partnerships
Vireo Health
David Vaillencourt
CEO and Founder
The GMP Collective
Cynthia Shelby-Lane
MD/CEO
ShelbyLaneMD PC
Paul Muchowski, Ph.D.
CEO & CSO
Defined Research
Cassin Coleman
Founder
Cassin Consulting
Allied Association Blog: Cal NORML Fights Ongoing Discrimination That Hurts Cannabis Businesses in California
Assemblymember Bill Quirk has introduced two bills sponsored by California NORML in this year’s legislative session that address ongoing human rights issues that are stumbling blocks for industry.
A pair of online surveys being conducted by California NORML is finding that up to 33% of respondents have been denied employment due to testing positive for cannabis, 19% have been denied prescription drugs by their doctor due to cannabis use, and up to 60% have stopped using cannabis because of drug testing by their employer or doctor.
This means as many as half of businesses’ potential customers aren’t buying cannabis products in California because of current laws. In addition, many Californians report they are underemployed because of their cannabis use, giving them less purchasing power at cannabis retailers.
The first bill to remedy this situation is AB 2188, which would end discrimination based on cannabis metabolites testing by California employers.
Testing or threatening to test bodily fluids for cannabis metabolites is the most common way that employers harass and discriminate against employees who lawfully use cannabis off the job. Cannabis metabolites are the non-psychoactive substances that can be detected in a person’s bodily fluids (mainly, urine and hair) for up to several weeks after they have consumed cannabis.
Testing positive for cannabis metabolites has no scientific value in establishing that a person is impaired on the job. When employers use cannabis metabolites tests to discriminate against employees or prospective employees, they are most likely discriminating against people who consumed cannabis when they were not at work.
Five other states (NV, NY, NJ, CT & MT) have passed laws in recent years protecting adult-use cannabis users’ employment rights, and 21 states protect those rights for medical marijuana users. Philadelphia, Washington D.C., and Atlanta also protect the rights of workers in their cities who use cannabis.
As in other states, the proposed California bill has exemptions for employers who are required to follow federal drug-testing mandates. Assemblymember Quirk’s bill does not bar employers from requiring that employees not be impaired on the job, and it does not prohibit other forms of testing, such as performance-based impairment testing or testing for THC, which may establish that a person has consumed cannabis in the past several hours.
Studies have shown that off-the-job cannabis use is not positively associated with elevated rates of occupational accidents or injuries, and that liberalized cannabis laws are associated greater labor participation, lower rates of absenteeism, declines in workers’ compensation filings, and higher wages.
The cities of Oakland and San Francisco have passed resolutions in favor of the employment rights bill’s language, and Cal NORML has been busy reaching out to unions and other stakeholders for support.
The second Cal NORML-sponsored bill to benefit California cannabis consumers — and the industry — is AB 1954, which seeks to protect the right of patients to medical treatment if they use medical cannabis, and the right of physicians and clinics to treat them.
Many physicians are under the mistaken impression that they can’t prescribe medication to patients who test positive for cannabis. The Quirk bill would clarify that physicians cannot be punished for treating patients who use medical cannabis, notwithstanding its illicit status under federal law.
A great many studies have shown cannabis is effective for pain and can help patients reduce their use of opiates. Cal NORML’s survey shows that 24-30% of respondents have increased their use of opiates or other medications due to drug testing by their doctor or employer. With an opiate overdose crisis continuing to affect California, we need to end policies that drive patients to use more dangerous and addictive drugs.
In Cal NORML’s membership polling, we have found that tax reduction is the #1 issue among our members. We are following and acting on 30-40 bills this year, including the various tax reform bills and other business-oriented proposals that have been introduced in the CA legislature this year, from a consumer rights standpoint.
Cal NORML has begun a Capital Campaign aimed at cannabis companies who do business in California to take us over the finish line on these important bills in 2022. We also offer business memberships with many perks, including discounts on NCIA memberships. We are always interested in hearing from our business members on how we can work together for cannabis consumers’ rights in California.
Ellen Komp is the Deputy Director of California NORML. Founded in 1972, Cal NORML is a non-profit, member-supported organization dedicated to reforming California’s marijuana laws. As the state chapter of the National Organization for the Reform of Marijuana Laws, we lobby lawmakers, promote events, publish newsletters, offer legal and consumer health advice, and sponsor scientific research. Check out our website at www.CaNORML.org.
Policy Council Conversations | 7.20.21 | The Medicine and Research of Cannabis
In this edition of our Policy Council Conversations series originally aired on Tuesday, July 20, 2021 we were joined by the six primary authors of NCIA’s recently released whitepaper on the Medicine of Cannabis for an overview designed to help inform and guide policymakers and medical professionals on the science, history, and uses of medical cannabis.
The Medicine of Cannabis: An Overview for Medical Professionals and Policymakers – https://bit.ly/3Bn1UBy
This publication was developed by scientists and doctors working with NCIA’s Policy Council and Scientific Advisory Committee, and promotes policies that facilitate further research and fair, legal access. On this webinar you’ll hear from the writing team itself, including physicians, veterinarians, and a PhD researcher as they discuss their paper and summarize what your doctor and policy maker needs to know.
Learning Objectives:
• Overview the history of medical cannabis and its prohibition in the United States
• Brief intro to the Endocannabinoid System
• Explore the cannabis plant
• Learn about different conditions cannabis can treat and the research that backs it up
• Discuss policy implications for cannabis including the need to deschedule
Speakers:
• Dr. Stephen Dahmer MD, Chief Medical Officer, Vireo Health
• Dr. Paloma Lehfeldt MD, Director of Medical Education, Vireo Health
• Dr. Paul Muchowski PhD, Founder/CEO/CSO, Defined Research
• Dr. Lynn Parodneck MD, Medical Practitioner
• Dr. Tim Shu DVM, CEO, VETCBD
• Dr. Casara Andre DVM, Founder, Veterinary Cannabis Education & Consulting
Member Blog: Drug Testing In Legal States – Corporate Policy vs. State Law
Currently, 33 states have legalized medical marijuana, and 11 others have given the green light to marijuana’s recreational use; however, the federal government still classifies any use of marijuana as illegal. This disparity creates a rift when employers go to test new employees for drugs.
Workplace drug testing began in the 1980s as part of former U.S. President Ronald Reagan’s “War on Drugs” campaign. At that time, employers wanted to ensure their workers were fit to do the job at hand. Since marijuana has become legalized in many states, employers in these states are unsure of new drug testing protocols; so are the states and legal systems themselves.
The resulting situation is a Catch-22.
Without testing, there would be more applicants for any given job and a larger pool of prospective workers. Therefore, employers would potentially get the strongest candidates. However, with testing, employers can assure they get drug-free employees who will be safe on the job.
But if marijuana is legal in some places and not others, who gets to decide where to draw the line?
Safety on the Job
Safety on any job is paramount, which requires workers who are alert and capable of completing the intricacies of the job.
According to Business News Daily, “The problem for employers is that impairment, because of marijuana, is usually much more difficult to detect and test for than alcohol. Unlike alcohol, it is very difficult for employers to determine if a positive drug test for marijuana is the result of drug usage during work or on non-work hours, so it is logistically simpler to just have an outright ban.”
Making the issue cut and dry is much easier on employers compared to making case-by-case decisions.
Additionally, any companies that accept federal money or hold contracts with the federal government will have to maintain drug testing protocols. In other business sectors, the line is not clear, which calls the legality of testing into question.
Legality of Testing
With the ever-changing state cannabis laws and the potential for cannabis to be legalized on the federal level, the nation is basically in a “trial and error” situation. Regardless, employers must keep current with these ever-changing circumstances to protect themselves and their employees.
The medical nature of marijuana usage further complicates the matter. Currently, 33 states issue medical marijuana cards, which permits users to use marijuana to treat medical issues. Business News Daily says, “Several states have specific laws protecting medical cannabis patients from employment discrimination. Typically, employers can require drug testing before employment and at random times, so long as there is no discrimination against medical marijuana users [who] are legally allowed cannabis for medicinal reasons.”
Besides the debate over medical marijuana cards, employers are stymied about what to do regarding recreational use as it pertains to the workplace. Since testing results can return positive weeks after the person smokes, there is really no way to tell if someone is a habitual user or it was a one-time event.
The states are divided. Currently, about 20 states will not allow discrimination in the workplace. But there is only one state that has gone so far as to say that recreational use of marijuana use is acceptable: Maine. Other states are starting to follow suit. Nevada law ensures that there can be no adverse outcomes for positive tests. And New York City will soon get rid of pre-employment testing altogether.
Other states are not so quick to change. For instance, workers in Illinois can still be disqualified as applicants or terminated as employees for a positive test. Currently, Illinois allows for the “good faith belief” that employees can consider workers under the influence if their speech or actions seem impaired.
Unfortunately, even the court systems do not agree. In some recent cases, the judge has sided with state rights, and in others, the federal appeal was victorious.
Moving forward, employees and employers need to continue the “wait and see” approach until federal and state employment laws catch up to the legalization of cannabis. For now, employers must determine their comfort levels with recreational marijuana use as it pertains to safety in the workplace.
Samantha Vanegas retains a MBA from the University of Florida Warrington College of Business. She works with the leaders of small start-up and growth-stage companies and non-profit organizations who seek temporary leadership to support growth and transitions. Whether for project-based work or as an interim manager, she is fabulous at supporting individuals and teams who are passionate about their work and need help bringing order to all the moving parts. She addresses common issues such as: how to build effective organizational infrastructure and systems; and, how to create and implement a strategy that will carry your business forward. She is a problem-solver who is able to envision the sum of the parts during and through transitions. She has a strong background in sales, operations, HR and marketing which elevates her expertise in assisting organizations with compliance intelligence and also with user, customer and employee experience surveys and solutions.
ath Power Consulting is an all-in-one resource for multi-modality survey and mystery shop research, competitive intelligence, compliance auditing, market analyses, employee training, and strategic consulting. Since 1997, we have helped our clients improve customer retention, build brand loyalty and advocacy, deepen employee engagement, measure compliance, maximize performance, and increase profitability – distinguishing them from their competition and giving them a commanding edge in the marketplace.
Member Blog: How CBD Helps Patients With Debilitating Conditions
As a dispensary budtender or owner, you always want to do everything you can to better serve your patients. Oftentimes, that means suggesting different strains and types of medical cannabis based on specific conditions and symptoms. To do that, you and the rest of the staff must understand the chemical makeup of marijuana, including the intricacies of cannabidiol and other cannabinoids.
Cannabidiol and Patients With Chronic Illness
Cannabidiol (CBD) is one of the two primary chemical compounds, or cannabinoids, found in the cannabis plant. The other is tetrahydrocannabinol, more commonly known as THC. However, unlike THC, CBD does not have the psychoactive properties that cause the user to feel high.
Instead, CBD alone can provide patients with many of the pain-relieving benefits of traditional marijuana products without creating that euphoric, but often debilitating, “stoned” feeling. This allows patients who prefer to avoid that effect — like children, the elderly, and recovering addicts — to still benefit from healing powers of medical cannabis.
So, CBD can be used to treat the pain that results from many conditions and symptoms, including cancer, epilepsy, lupus, Parkinson’s disease and related diseases. You can also use CBD to treat mental health conditions, such as anxiety, depression, obsessive-compulsive disorder, insomnia, and schizophrenia.
How Can Budtenders and Dispensary Owners Talk to Patients About CBD?
As budtenders, part of your job is helping patients understand how using CBD to treat chronic conditions can help them. Remember, most people probably have not heard of CBD, and patients may be hesitant to learn about it. Start by explaining the benefits of using only this cannabinoid, such as being able to avoid the high while still finding pain relief. If they seem interested, encourage them to ask questions and tell them more about the specific products that would best treat their symptoms.
A general rule of thumb when discussing marijuana strains is that indica strains — as well as indica-dominant hybrids — have higher CBD content, while sativa strains and sativa-dominant hybrids have a higher THC content. Of course, every strain has a different ratio of CBD-to-THC, but there are many that have little to no THC at all.
While the CBD strains a budtender should recommend will depend heavily on the patient’s specific symptoms, here are a few examples you can choose from:
Swiss Gold
Sour Tsunami
ACDC
Valentine X
Harlequin
Frequently Asked Questions About Cannabidiol
The best way to prepare for patients’ questions is to think about what they may be. Here are three common concerns patients will likely have about CBD:
Is It Safe for Children?
Yes — in fact, it’s incredibly beneficial for children suffering from epilepsy, specifically. One study found that epileptic children experienced an 80 percent reduction in seizures when they used cannabis with a high CBD content.
Will It Still Work?
While everyone reacts to marijuana differently, countless studies have shown CBD is effective in treating all sorts of health conditions and symptoms, like the ones discussed above.
How Can I Ingest CBD?
You can ingest or administer CBD the same ways you would take any other form of marijuana, including by smoking or vaping the herb or oil, eating or drinking an edible product, applying it as a topical lotion or taking a tincture or capsule. However, be sure to check your state’s laws on how you can take your medicine, as each has different guidelines.
Learn More About CBD and Patients With Chronic Illness From MarijuanaDoctors.com
Interested in learning more about how your dispensary can better serve its patients? MarijuanaDoctors.com provides patients with the resources needed to find a trusted doctor in their area and to find reputable dispensaries so that obtaining medication is simple. Check out our other resources at MarijuanaDoctors.com for more information. For even more benefits, register your dispensary with our site today.
Juicing is an increasingly popular health trend. Many people, from nutritionists to athletes, are consuming pressed vegetable juices to get the nutrients contained in leafy greens like spinach and kale. But what about cannabis?
Health Benefits of the Cannabis Plant
The leaves of the cannabis plant are rich in antioxidants, polyphenols and antibiotics, along with cancer-reducing and anti-inflammatory compounds. In fact, the U.S. federal government found in pre-patent research that CBD, which is a cannabinoid found in raw cannabis, is a stronger antioxidant than vitamins C or E.
Along with its nutritional value, raw cannabis can provide therapeutic effects and promotes basic cell function – activating receptors in your brain, releasing antioxidants, and removing damaged cells from the body.
Studies have also shown that consuming raw cannabis has the potential to treat lupus, arthritis and neurodegenerative diseases, help stimulate appetite and decrease nausea, prevent the spread of malignant prostate cancer cells, and prevent cell damage that can lead to serious illness and poor health.
Consuming Raw Cannabis
Consuming raw cannabis does not cause the “high” feeling that one gets when smoking cannabis or consuming it via edibles. This is beneficial for those who do not enjoy the psychoactive feeling often associated with marijuana.
By consuming the plant raw, one can receive all the nutritional and health benefits of the plant without feeling stoned. In fact, it’s been reported that you lose 99% of the health benefits of the cannabis plant when you smoke or cook it.
Juicing marijuana is the easiest and most convenient and way to consume the nutrients found in raw cannabis. Juicing the leaves of raw marijuana extracts essential minerals, vitamins and antioxidants, including:
Iron
Zinc
Calcium
Potassium
Selenium
Carotenoids
In terms of dosage, one suggestion is to consume 30g of fresh cannabis leaves per day.
Tips for Juicing Raw Cannabis
Add in 2- to 4-inch buds and 15 large fan leaves into a juicer. You can use the juice in smoothies with other vegetable and fruit juices, or freeze the juice to make ice cubes. Freeze leftover leaves to preserve their nutrients for future juicing.
Additional Tips for Juicing Cannabis:
Don’t use dry cannabis or nuggets that have already been cured for smoking.
Look for small, sticky crystals on the flowers and make sure that buds are amber colored.
Combine 1-part cannabis juice to 10-parts carrot juice to help reduce cannabis bitterness.
Additional Raw Cannabis Information
When incorporating raw cannabis into your diet, there are side effects to consider, including allergic reactions, possible ingestion of insecticides and pesticides, and compromised immune system from possible pathogenic exposure.
Consuming raw cannabis isn’t the best solution for fast symptom relief. Typically, it takes about three days to notice benefits. For some, the benefits may not be noticed for four to eight weeks as the nutrients build in your system.
To learn more about the benefits of cannabis, or to find a medical marijuana-recommending physician near you, visit MarijuanaDoctors.com.
Jason Draizin is the Founder and CEO of the Medical Cannabis Network and MarijuanaDoctors.com. Founded in 2010, MarijuanaDoctors.com is a secure portal for qualifying patients looking to connect and schedule an appointment with medical marijuana-certified physicians. The site has assisted in the certification of more than 300,000 patients in the U.S., and has established a network of more than 700 physicians nationwide.
Partner Blog: Ohio’s Medical Marijuana Program Begins Taking Shape
by Thomas Rosenberger, Executive Director of NCIAO
More than a year after Ohio legalized medical marijuana, the first licenses have finally been awarded. The Ohio Department of Commerce ended months of speculation by announcing 12 level II cultivator license winners on November 3rd, and 12 level I cultivator license winners on November 30th.
These 24 winners are now responsible for growing the supply of medical marijuana Ohio’s patients will use, a population estimated to be in the hundreds of thousands. The medical marijuana market in Ohio is expected to be worth $300-400 million once it matures, making the limited number of licenses available immensely valuable.
While we now know who the 24 cultivators will be, Ohio’s medical marijuana program is still nine months away from its September 8th, 2018 deadline to be operational. Processing, dispensary and testing licenses have all yet to be awarded, and already controversy and lawsuits are threatening to derail and delay the program.
It’s a scenario we’ve seen repeatedly in other states such as Maryland, and a scenario for which the industry must work together to prevent in Ohio. The National Cannabis Industry Association of Ohio was formed in July to foster collaboration between members, promote best practices and to serve as the voice of the industry in Ohio.
We’ve spent the past 5 months advocating for the industry and working to provide feedback to state regulators on various aspects of the program. Moving forward, our priority will be on ensuring Ohio’s program meets its statutory deadlines and licensed cannabis businesses are able to begin serving Ohio’s patients by September 8th, 2018.
Now more than ever, it’s crucial the industry come together to ensure Ohio’s medical cannabis program is not delayed. Ohio’s patients have waited long enough for relief, and the industry has a responsibility to ensure they wait no longer.
NCIAO is the Ohio affiliate of the National Cannabis Industry Association, the nations only industry-led organization engaging in legislative efforts to expand and further legitimize the legal cannabis market in the U.S.
The Future of Medical Cannabis Reform – Now What?
by Michelle Rutter, NCIA Government Relations Manager
Late in the evening of September 6th, the House Rules Committee held a hearing to discuss amendments to the upcoming appropriations bill that will fund the federal government for the upcoming fiscal year. The Rules Committee is used by House leadership to maintain control over the House floor, and is heavily stacked in favor of the majority party (by a 2:1 ratio).
Unfortunately, the committee decided not to allow the Rohrabacher-Blumenauer amendment (formerly the Rohrabacher-Farr amendment) to move forward for a vote on the Floor. Despite the fact that 46 states have legalized some form of cannabis, 90% of the public supports medical marijuana, and over 70% think the federal government should not interfere with state marijuana reforms, the Rules Committee singlehandedly decided to strip out the language protecting states’ medical marijuana laws that have been in law since 2014.
Although this came as no surprise, it is still disappointing. So, what’s next going forward? There are a couple of possible scenarios.
Scenario 1: In July, the Senate Appropriations Committee passed an amendment offered by Vice Chairman Patrick Leahy (D-VT) by a voice vote. The Leahy amendment is identical to the Rohrabacher-Blumenauer amendment and would protect medical cannabis businesses and patients for another year. If this legislation passes the Senate, the opportunity still exists for Congress to reconcile the differences and agree to maintain the current protections in medical cannabis states.
Scenario 2: There are rumors circulating that Congress will pass a funding bill for Hurricane Harvey relief and that this bill would include a debt ceiling increase and continue funding the federal government through mid-December. If this happens, the Rohrabacher-Farr amendment will continue to protect medical cannabis patients and businesses until a new appropriations bill is passed.
Scenario 3: Neither the House or the Senate agree to maintaining this provision, and Congressional protections for states’ medical cannabis laws disappear in the short term. Although this is the worst scenario of the three listed here, the opportunity still exists for Congress to re-insert this provision during next year’s budget negotiations.
NCIA will continue to advocate and communicate with Members of Congress on the behalf of the cannabis industry. While the House Rules Committee has made a disappointing decision, there is still hope that the Rohrabacher-Blumenauer/Leahy amendments will be included in federal law for yet another year. As we continue to represent our member-businesses, we will be vigilant in our efforts to bring about the best possible positive outcome in the current political climate.
Senate Subcommittee Just Says Yes… To A Hearing
by Michelle Rutter, Government Relations Coordinator
Earlier this month, the Senate Judiciary Subcommittee on Crime and Terrorism held a hearing entitled ”Researching the Potential Medical Benefits and Risks of Marijuana,” which was presided over by Sens. Graham (R-SC), Whitehouse (D-RI), Klobuchar (D-MN), Grassley (R-IA), and Blumenthal (D-CT). Witnesses included Sen. Kirsten Gillibrand (D-NY) and Sen. Kirsten Gillibrand (D-NY), federal officials from NIDA (National Institute on Drug Abuse), NIH (National Institute of Health), and the FDA (Food and Drug Administration), and members of the medical and legal community. For more information on the hearing and the witnesses, click here.
The first panel included Sens. Gillibrand (D-NY) and Booker (D-NJ), who both testified on the benefits medical cannabis can provide and noted that they are both original co-sponsors of the Compassionate Access, Research Expansion, and Respect States Act (S. 683), better known as the CARERS Act. Some of the key points that the Senators mentioned during the hearing included removing cannabis from its designation as a Schedule I drug, dismantling NIDA’s monopoly on cannabis used for research, and the urgent need to ease restrictions to allow for more research.
The next panel was comprised of two government agency officials: the Director of the Division of Extramural Research at the National Institute on Drug Abuse at the National Institutes of Health, and a doctor who is Deputy Center Director for Regulatory Programs at the FDA. Both panelists repeatedly stressed the importance of continued research into the therapeutic and medicinal benefits of cannabis, as well as the development of cannabis-based drugs. The FDA official also highlighted that the DEA is currently reviewing a recommendation on cannabis’s designation as a Schedule I drug, and the decision is pending.
The third panel included two doctors and a lawyer representing the DEA. The first doctor noted that THC and CBD do have therapeutic value but stressed the need for more research to determine if/how to mitigate any negative side effects of medical cannabis use. The second doctor on the panel is a well-known cannabis opponent, whose testimony sounded more like “reefer-madness” than a Senate hearing on cannabis in 2016. The lawyer present gave a moderately short statement, but did state that the DEA regulations around Schedule I drugs already provide a great deal of flexibility for research and can and are waived to allow legitimate studies and that the reclassification of cannabis to Schedule II would have little impact on the barriers to research – a statement that most in the cannabis community would strongly disagree with.
During questioning, Sen. Graham (R-SC) asked if the witnesses believed that cannabis should be re-scheduled as a Schedule II drug. Both the FDA official and the NIDA/NIH official weighed in, and with the same conclusion: more research is needed in order to make that determination. Chairman Graham also asked how to best facilitate medical cannabis research, which was answered by the DEA’s lawyer, who responded that the “flexibility” in the regulatory system could allow for it.
What does it mean?
Past Congressional hearings regarding cannabis have typically focused on the harms, not the benefits, of marijuana. As such, it’s a positive sign that the Chairman of the Senate Judiciary Subcommittee on Crime and Terrorism, Lindsey Graham (R-SC), held a hearing on the potential therapeutic benefits of medical cannabis. The main takeaway from the hearing was the desire from all parties – Senators, government officials, and medical professionals alike – for more research on cannabis, its compounds, and its effects.
Regardless, this hearing shows the progress that the industry has made in Congress and the momentum building nationwide behind the cannabis movement.
NCIA Member Profile: The Giving Tree Wellness Center
This month, NCIA checks in with Lilach Power, Managing Director at The Giving Tree Wellness Center based in Phoenix, Arizona. The Giving Tree Wellness Center has been a member of NCIA since September 2013, taking an holistic approach in supporting their clients by offering a range of medical marijuana products along with alternative healing methods, including massage and acupuncture, to promote the best quality of life possible through both their North Phoenix and Mesa locations.
Cannabis Industry Sector:
Medical Cannabis Providers
NCIA Member Since:
2013
How do you uniquely serve the cannabis industry?
Lilach Power, Managing Director at The Giving Tree Wellness Center
When Gina and I started our business, we had a vision of creating a safe and inviting environment for patients, and I think we have succeeded. We have beautiful spa-like stores that are very inviting. We do not have the traditional pot shop that I think a lot of people think of when they envision a dispensary. There are no bars, bullet-proof glass or tiny bank windows. This is truly a place to get help and find quality medicine.
We understand that patients might be intimidated coming to a dispensary at first, so we like to make them as comfortable as possible. We have private consultation rooms where patients can really sit down and be comfortable discussing their medical issues and see what options we have for them. We encourage patients to schedule one-on-one consultations with our patient consultants or with our medical director (my business partner, Gina Berman, M.D.). We never up-sell or push patients to buy anything. Our goal is only to find the ideal medicine for each patient. We never rush patients – whether they are a first timer, or this is their hundredth visit.
Gina Berman, M.D. of The Giving Tree Wellness Center
The Giving Tree takes pride in its local community philanthropic endeavors. We participate in two big fundraising events annually. Our next one is on April 11th, the Take Steps for Crohn’s and Colitis walk. We match all donations and I am proud to say many vendors have been participating, so we are getting the industry involved in our community as well. Our other big annual event is the breast cancer Walk for the Cure in the Fall. In addition, we raise money and hold canned food drives during the holiday season to help local folks in need.
Realizing that there are patients for whom the cost of this medicine is a burden, we started our own program for discounted medicine for patients on SNAP or long-term disability. We also deliver for patients with physical hardship, with no delivery charge.
Why should patients looking for medical cannabis services go to The Giving Tree Wellness Center?
Service and quality: We have an elite team of patient consultants (PCs) and we are patient-focused. Our PCs are truly passionate and have a fund of knowledge – I am so proud every time I walk into the dispensary and see how much they really care. Our patients really do become part of The Giving Tree Family.
Our medicine: We grow a majority of the medicine we offer. We stress quality over quantity and grow strains based not on their yield but on the merits of their quality and variety. We do not use pesticides, and we always use an independent, third-party lab to test all our medicine. We definitely have learned a lot during this process and our goal is to make each harvest better than the last. We are proud each time we harvest and cure and see our medicine on the menu.
The Giving Tree Wellness Center – Arizona
Can you give us some insight into the medical cannabis community in Arizona, where it’s been and where it’s headed?
Arizona is a really unique cannabis community. There are not many medical marijuana dispensaries operating and there won’t ever be, per statute. That really takes the competition out of the equation for the most part and we can really just focus on creating and maintaining a well-regulated and upstanding industry where the focus is truly just on the patients.
Also, as time goes on and more and more Arizonans are helped by cannabis, our communities will hopefully embrace us as offering a much-needed service instead of being thought of as the criminal-laden underbelly of the cities. The regulated stores are dramatically different than any black market operation. I think this will become more apparent as time goes on as more people in the community are exposed to state-regulated dispensaries.
We see the need for an organization to bring us all together and represent us on the national stage. There is no other organization that does that. We see the importance in supporting it, becoming part of it, and hopefully being more involved in the future. It is the only way to move our industry forward.
If you are a member of NCIA and would like to contribute to the NCIA blog, please contact development officer Bethany Moore by emailing bethany@thecannabisindustry.org.
Inside the Illinois Medical Marijuana Program with the Illinois Cannabis Industry Association
The number of licenses for cultivation centers and dispensaries are quite limited – only 22 available for cultivation centers and 60 for dispensaries. What are officials with the Illinois Department of Agriculture looking at in applications to determine who will be awarded a license? Is there a chance to earn bonus points in any category?
Dan: The Department of Agriculture will be grading on a number of different features but the grow plan and horticultural experience will be heavily weighted in the scoring. In the event of a tie between competing applications for a single license the application with the higher scored grow plan will be awarded the license.
Ali: The main required categories don’t have specific bonus points available, but each application has an entire Bonus Section of areas that are not required but available for applicants to gain additional points if the required sections meet a certain score threshold. The Bonus Section areas include Labor and Employment Practices, a Research Plan, a Community Benefits Plan, a Substance Abuse Prevention Plan, a Local Community/Neighborhood Report, an Environmental Plan as well as additional points for Illinois-based applicants and businesses that are minority-owned, female-owned, veteran-owned, or owned by a person with a disability.
Dan Linn, ILCIA
State officials are making security a high priority for all applications. What kind of standards must applicants meet in their business plan regarding security measures?
Dan: Applicants will need to have full seed-to-sale inventory tracking accessible in real time by the Illinois State Police. Security measures will need to include listings of where the bulletproof glass is on the floor diagram of the dispensary, the camera field of vision, the proper-sized televisions to monitor the cameras, as well as background checks on everyone involved in the program.
What is the climate regarding banking access in Illinois? Have any banks come out to say they will allow cannabis businesses to open bank accounts?
Dan: Some banks are just unwilling to work with the cannabis industry. None have publicly come out as being willing to engage this industry, but there are a number of smaller community banks that are handling accounts for cannabis businesses in Illinois.
September 22 is the deadline for submitting applications to open a cultivation center or dispensary. What does the timeline look like for when licenses will be awarded and when is it expected that dispensaries will actually be selling product?
Ali: Recent public reports indicate that licenses will likely be issued later in the fall, probably in November or December. Based on that timeline dispensaries should be open with product on the shelves for patients in late spring/early summer of 2015.
How many expected applications for cultivation centers and dispensaries will be submitted by the September 22 deadline?
Ali: It is likely that there will be an average of at least a few applicants for each of the 82 available licenses, with total applicants numbering anywhere from 250-600.
Applications also just opened for qualifying medical patients to apply for access to medical marijuana. What is the timeline for qualifying patients to apply and when will patients find out if they are accepted into the program?
Ali: Patients with last names beginning A-L can apply now through Oct 31. Patients with last names beginning M-Z can apply Nov. 1-Dec. 31 and beginning Jan. 1 there will be open year-round enrollment for all patients. The state has 30 days by law to process a patient application, plus 14 days to mail it. This means that patients should expect to receive their approval or denial within 45 days of submission.
What are some of the regulations regarding edibles and other infused products?
Ali Nagib, ILCIA
Ali: Edibles and other infused products can be produced, but only those that can be kept at room temperature safely; products that require hot-holding or refrigeration are prohibited. Otherwise a wide range of infused products can be produced, and the state regulations have some fairly specific guidelines on the some of the production processes (e.g. which solvents can be used to produce concentrates) in addition to robust testing and labeling requirements.
Dan: Additionally, edibles and infused products must be produced in a sanitary kitchen and cannot look like candy or any name-brand food items.
What is the anticipated cost per ounce once product starts becoming available?
Dan: $250-400 is the estimated initial expected cost per ounce.
Ali: The early stages of the Medical Cannabis Pilot Program are likely to see a wide range of prices and substantial fluctuations as early supply and demand features work themselves out. It is almost certain that initial prices will be above those currently found on the illegal market, if not substantially so, but how the industry will react to the patient demand is uncertain.
The Illinois program is a pilot program that currently expires in 2017, and lawmakers must renew or extend the program at that time. What do you think lawmakers will be considering when deciding to renew or extend the program when the time comes?
Dan: They will be examining any instances of diversion, shenanigans, positive health experiences for patients, jobs created, who is the next President of the United States, how much revenue the program is creating, and probably what the overall public opinion of the program is.
Ali: We expect that by early 2017 the local and national landscape on cannabis policy reform will have continued to progress to the point that we won’t be debating whether or not to extend the pilot program but rather how and when to transition to a full tax-and-regulate framework and how to incorporate medical cannabis patients into it.
Illinois Medical Marijuana Program Accepting Applications
After months of planning, the state of Illinois has officially begun accepting applications from potential medical marijuana patients and business owners for its Medical Cannabis Pilot Program.
On Tuesday, September 2, Illinois officials began processing paperwork from potential patients whose last names begin with the letters A through L. By the end of the first week, according to the Chicago Sun-Times, more than 2,000 applications had been received. (Patients with names beginning with the letters M through Z will be eligible to apply beginning November 1.)
The pilot program’s coordinator, Bob Morgan, expressed excitement over the large number of patient applications in the very early days of the process. “It’s a strong indication of the interest in the program,” he told the Sun-Times.
The dispensary and cultivation licensing process promises to be a bit more challenging. With only 22 licenses available for cultivation centers and 60 for dispensaries, competition will likely be stiff, especially for the large Chicago market. (See this interactive graphic from the Chicago Daily Herald for more details on where the 60 dispensary licenses will be allocated.) The application process is extensive, and the capital requirements for applicants are steep. Even successful applicants will have to consider the “pilot” nature of the program, which includes the possibility that it could sunset after a few years.
As Troy Dayton, CEO of NCIA Sustaining Member The Arcview Group, told Chicago’s WBEZ Radio, “[Business owners] had better have a lot of money in the bank because it may be a long ramp up before they can make their businesses profitable.”
Despite these challenges, medical marijuana is coming to Illinois, and with it comes opportunity. Soon, the fifth-largest state in the nation will offer patients the potentially life-changing choice to access medical marijuana, and that’s progress to celebrate.
Are you applying for a dispensary or cultivation license in Illinois? Share your experience in the comment section below.
Lady Business: Bethany Moore from National Cannabis Business Association | Ladybud Magazine
LADYBUD: You work at the National Cannabis Industry Association NCIA — what is it that you do there?
BETHANY: My primary role at NCIA is focused on membership development. I foster deeper relationships with our existing members, as well as seek out relationships with cannabis companies that are not yet a part of NCIA. I travel quite a bit for the events we do all around the country, and I enjoy that opportunity to feel the connection of this growing community from one end of the country to the other. I obviously recruit new members, but also do fun stuff like work with members to write blog posts, match members with event sponsorship opportunities, and otherwise assist in development for the organization. The future is bright and I’m honored to be in this role at this time, after years of being a volunteer activist for drug policy reform issues, when honestly, I didn’t see this whole legalization thing coming as soon as it did. I’m pleasantly surprised about the forward progress of the movement recently and look forward to helping the industry and movement progress forward responsibly and ethically.
NCIA’s 2nd Annual Southwest CannaBusiness Symposium Brings Together Cannabis Industry Leaders in Las Vegas
On Saturday, August 23, NCIA hosted cannabis industry professionals for a day of information-packed sessions at its second annual Southwest CannaBusiness Symposium in Las Vegas, Nevada. Opening remarks featured Aaron Smith, executive director of NCIA, Congresswoman Dina Titus (D-Las Vegas) and Nevada State Senator Tick Segerblom (D-Las Vegas). Comments from the panelists focused on the local political atmosphere, touching on how Nevada, having passed legislation last year to set up a statewide medical program, is currently reviewing applications for licenses for medical marijuana dispensaries and cultivation centers. Additionally the Nevada legislature will consider a full legalization initiative during the 2015 session, although passage would require a 2/3 vote in both chambers. If the measure fails in the legislature, Nevada voters will have a chance to directly vote on legalization as a ballot initiative in 2016. Both Rep. Titus and Sen. Segerblom encouraged attendees to reach out to them and keep an open dialogue so that they can best represent the industry by understanding its needs.
The second panel, titled “Infused Products & Edibles Discussion,” featured experts in the fields of extraction, analytical testing, edible manufacturing, and retailing of infused products. Discussed on this panel were the importance of analytical lab testing to ensure quality products, the basics of different types of extraction methods, how to find your edible niche and establishing a brand, and the importance of educating your customers on the effects of infused products. Featured on this panel were Andy Joseph of Apeks Supercritical, Adam Mintz of Steep Hill Halent Labs, Julianna Carella of Auntie Dolores and Étienne Fontan of Berkeley Patients Group.
After these first two panels, attendees broke for a networking lunch where they could talk one-on-one and meet others already involved or looking to get into the industry. Walking around the conference floor you could hear conversations such as “What are current marketing regulations surrounding the sale of cannabis and infused products like in CO or WA?” and “How are you involved or wanting to be involved in the industry?” as well as lengthy discussions on attendees’ experiences regarding the Nevada application process which ended earlier in the week. Attendees also had the chance to visit sponsor booths to find out more about their products and services. The symposium’s sponsors this year included Eden Labs, MJ Freeway, Steep Hill Halent Labs of Nevada, Apeks Supercritical, HempMeds PX, and the ArcView Group.
Following lunch, the panel “Maintaining Responsible Business Practices” featured several distinct topics regarding establishing a culture of responsible practices within your business. The first topic highlighted the importance of setting standards of practice and self-regulation, especially regarding implementing programs that encourage customers to keep marijuana out of the hands of youth. Other topics included information on managing employees and effective human resource strategies, trademarking and protecting your brand, and an array of sustainable business practices that aid in lowering waste and increasing profits while contributing to a cleaner environment overall. Featured on this panel was Leslie Bocskor of Electrum Partners LLC, Carole Richter of CRichter ~ HR Consulting, LLC, Amanda Conley of Cobalt LLP, and Alex Cooley of Solstice Co-op.
Michael Correia, director of government relations for NCIA, followed to provide a federal update about what’s been happening in Congress. We’ve seen some positive movement within the House of Representatives recently. This past May, for the first time in history, a chamber of Congress passed pro-marijuana legislation. Congressmen Dana Rohrabacher (R-CA) and Sam Farr (D-CA) introduced an amendment to the appropriations bill covering the Department of Justice that limited the Department of Justice and DEA from interfering with states moving forward on medical marijuana. It passed 219-189, with an astonishing 49 Republicans supporting. Currently, the legislation is in the Senate and has Senators Rand Paul (R-KY) and Cory Booker (D-NJ) as co-sponsors. In addition, on July 16th, the House passed a similar amendment that would prohibit the Department of Treasury from penalizing banks that do business with state-compliant marijuana businesses. It passed 231-192, with 45 Republicans supporting it.
Rounding out the update was the mention of a potential upcoming issue that may have large implications for any marijuana cultivators using federal water reserves to grow. The Bureau of Reclamation, which manages water for the federal government, has stated that federal water should not be used for state-legal marijuana cultivation, since marijuana remains federally illegal. Although it is not yet a large issue, and so far the Bureau has only said that they will refer such cases to the Department of Justice, it looms as a potential trouble spot in Colorado and Washington State, and because Nevada gets most of its water from federal sources, it will likely become an issue in that state as well. Currently the Bureau of Reclamation is moving cautiously, and a group of senators have asked the Justice Department to give further legal guidance on this. NCIA will be providing updates on this issue as they are available.
The panel “Effective Messaging for Cannabis Professionals” rounded out the day and focused on tactics to use when talking with the media to communicate your message most effectively. Taylor West, deputy director of NCIA, provided advice focused on talking about a medical use program. She touched on the story of the development of the medical cannabis program in Nevada and the importance of emphasizing passion and compassion for patients. That story includes the quality of your product, your dedicated service, and your compassionate care in providing medicine to patients to improve their lives. Joe Brezny, executive director of the Nevada Cannabis Industry Association, provided advice on speaking with the media about the upcoming Nevada full-legalization measure. He touched on the Nevada Regulate Marijuana like Alcohol campaign messaging, which emphasizes that regulated marijuana is no worse than alcohol, that the marijuana market in Nevada is already present but in a black market run by cartels and drug dealers, and that legalizing and regulating marijuana is proving to work in states that have done so already. His key takeaways were that state-specific messaging is important to make it relevant to the political landscape of that state.
Thanks to everyone who joined us in Las Vegas for another successful event. Make sure you don’t miss any other great educational and networking events we have coming up!
NCIA Member Profile: Canuvo Medical Cannabis Dispensary
NCIA recently had an opportunity to speak with Glenn Peterson, co-founder of Canuvo, a state-licensed medical cannabis dispensary in York County, Maine. Canuvo offers naturally grown medical cannabis in a wide selection of strains, private discreet consultations with trained staff, public workshops, and education.
Cannabis Industry Sector:
Medical Cannabis Provider
NCIA Member Since:
2013
How do you uniquely serve the cannabis industry?
I am a patient, former caregiver, and possibly the last regular person to obtain a contested state license in a highly regulated state and finance the project entirely myself. I have done every job in cultivation, manufacturing, and dispensing until I could replace myself with the best staff possible, which gives me a unique understanding of my business and this industry. I am also blessed to have my wife, sister, and daughter work by my side and watch my back at Canuvo. As a vertically integrated state, we cultivate & manufacture everything we sell. In addition to our 80-strain library, we offer concentrates, edibles, lotion, salves, capsules, and oils. We love coming up with new delivery systems!
I have been the President of the Maine Association of Dispensary Operators (MeADO) since its inception in 2012. Each year MeADO has passed multiple bills into law, both on their own and in collaboration with other stake holders. As the President of MeADO I have an active presence in our statehouse lobbying for patients and dispensaries. Personally I attend as many regional and national NCIA events as possible including Lobby Days in DC.
Why should patients looking for medical cannabis services go to Canuvo?
Selection: We have a large strain library of over 80 strains and growing, 15 to 24 of which are available each day. With so many different patient preferences, goals, and needs, it is important to us to offer an expansive, constantly rotating menu.
Education: The industry is expanding and there is always information to share regardless of how seasoned the patient is. In addition to a wide selection of dosing options, we have a loaning library and the opportunity for patients to have a one-on-one consultation. This way we can get to know our patients as individuals, offer guidance, and help them understand why and how their medication works.
Privacy: We are located in a former doctor’s office and are fortunate enough to dispense out of multiple examining rooms. This allows the patient to discuss their medical goals and concerns without being overheard.
What is the medical marijuana community like in Maine? Where do you see it going?
Maine has had a medical cannabis program since 1999. It allowed patients to grow for themselves or have a caregiver (who is limited to 5 patients) grow for you. In 2010 the dispensary model was added to increase patients’ access to safe, inspected medical cannabis. Our edibles are produced in a state-licensed kitchen, our cannabis is grown without pesticides, and we keep normal business hours. The dispensaries added a level of professionalism previously lacking in the industry.
I anticipate legislation and referendum efforts for adult use in Maine shortly. I believe all adults should have access for personal use in addition to medicinal. Though most adults can benefit, I hope to exempt qualified medical patients from the sales tax, excise tax, and driving under the influence provisions. There is no lack of cannabis in Maine. There is no need for the steep ‘sin tax‘ in Maine like Colorado and Washington to entice support. It only serves to drive the consumer to the unregulated, non-taxpaying black market. Though our program in the state of Maine is small compared to other states (only 8 licensed dispensaries), our state’s cannabis program scored #1 in the country last month by Americans For Safe Access as based on a criteria of 40 considerations.
Why did you get involved in NCIA?
Glenn Peterson, Canuvo Co-Founder
We learned of NCIA while consulting with Kayvan Khalatbari from Denver Relief Consulting. It made sense for us to join so we could meet and learn from other members, contribute to the effort, and keep our fingers on the pulse of the industry. The member contacts have been invaluable. NCIA is the spear point for the cannabis industry and efforts to bring forth meaningful needed change to our industry.
If you are a member of NCIA and would like to contribute to the NCIA blog, please contact Development Officer Bethany Moore by emailing bethany@thecannabisindustry.org.
Is Medical Marijuana the Answer to the Prescription Painkiller Epidemic?
A new study suggests that access to medical marijuana could dramatically reduce the number of prescription painkiller deaths in the United States.
Research published this week in JAMA Internal Medicinereports that states that have legalized medical marijuana saw 25% fewer deaths from prescription painkiller overdoses between 1999 and 2010 than states where cannabis was illegal.
As the Washington Post reports, “That meant 1,729 fewer deaths than expected in 2010 alone, and states saw their overdose rates generally improve each year after their medical marijuana laws were passed, researchers found.”
The CDC reports that 100 people die from drug overdoses every day in the U.S., and prescription painkillers account for nearly three-quarters of that number. Drug overdose death rates have more than tripled since 1990. Consumer Reports recently published an in-depth report on the dangers posed by Americans’ overuse of painkillers.
The JAMA Internal Medicine research was not designed to determine if access to medical marijuana is the primary cause of lower prescription painkiller death rates. But the data suggests there would be significant value in more research on medical cannabis as a replacement or supplement for standard prescription painkiller regimens.
Previous research has shown that patients who use marijuana in addition to prescribed opiate painkillers can manage their pain with significantly lower doses of the opiates than patients using prescription drugs alone.
Have you or any of your patients made the transition from opiates to medical marijuana for pain management? Share your story in the comments section below.
This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.
By Ellen Komp, 
Ellen Komp is the Deputy Director of California NORML. Founded in 1972, Cal NORML is a non-profit, member-supported organization dedicated to reforming California’s marijuana laws. As the state chapter of the National Organization for the Reform of Marijuana Laws, we lobby lawmakers, promote events, publish newsletters, offer legal and consumer health advice, and sponsor scientific research. Check out our website at 
Samantha Vanegas retains a MBA from the University of Florida Warrington College of Business. 
These 24 winners are now responsible for growing the supply of medical marijuana Ohio’s patients will use, a population estimated to be in the hundreds of thousands. The medical marijuana market in Ohio is expected to be worth $300-400 million once it matures, making the limited number of licenses available immensely valuable.
t year to set up a statewide medical program, is currently reviewing applications for licenses for medical marijuana dispensaries and cultivation centers. Additionally the Nevada legislature will consider a full legalization initiative during the 2015 session, although passage would require a 2/3 vote in both chambers. If the measure fails in the legislature, Nevada voters will have a chance to directly vote on legalization as a ballot initiative in 2016. Both Rep. Titus and Sen. Segerblom encouraged attendees to reach out to them and keep an open dialogue so that they can best represent the industry by understanding its needs.
regarding the Nevada application process which ended earlier in the week. Attendees also had the chance to visit sponsor booths to find out more about their products and services. The symposium’s sponsors this year included 
moving cautiously, and a group of senators have asked the Justice Department to give further legal guidance on this. NCIA will be providing updates on this issue as they are available.
